{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-044747","form_type":"8-K","ticker":"SKYE","cik":"0001516551","company_name":"Skye Bioscience, Inc.","filed_at":"2026-06-22T21:53:56+00:00","discovered_at":"2026-06-23T10:05:00.236484+00:00","generated_at":"2026-06-23T10:06:51.714902+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Skye Bioscience transfers Nasdaq listing to Capital Market after equity deficiency; bid price non-compliance continues","bullets":["Nasdaq approved transfer from Global to Capital Market effective June 23, 2026 due to stockholders' equity of $9.0M below $10M requirement.","Company previously disclosed bid price below $1 for 30 consecutive days; compliance period runs to Sept 14, 2026.","Ticker symbol remains SKYE; transfer to Capital Market allows lower $3M equity standard.","Company monitoring bid price and considering options but no assurance of regaining compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-044747","json":"https://secwatch.observer/filing/0001628280-26-044747.json","markdown":"https://secwatch.observer/filing/0001628280-26-044747.md","text":"https://secwatch.observer/filing/0001628280-26-044747.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026044747/0001628280-26-044747-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026044747/skye-20260618.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T10:06:51.714902+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}